SCHEMBL17769156

SCHEMBL17769156

Cc1cnn(-c2nc(N)c(C(=O)NCc3ccccc3C(F)(F)F)nc2Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.48
▸ CNR2 P34972 1/20 0.48
▸ MEN1 O00255 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ MAPK10 P53779 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HSD17B13 Q7Z5P4 1/20 0.42
▸ P2RX7 Q99572 2/20 0.42
▸ KLKB1 P03952 4/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ ADORA2A P29274 2/20 0.40
▸ ADORA1 P30542 2/20 0.40
▸ PTGES O14684 2/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ CCR1 P32246 1/20 0.39
▸ EPHX2 P34913 4/20 0.39
▸ ADORA2B P29275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17768986 0.87 ADORA2A (0.47) HSD17B13KLKB1ADORA2AADORA1PTGES
SCHEMBL17768753 0.85 CNR1 (0.49) CNR1CNR2MEN1CYP1A2CYP2D6
SCHEMBL17768739 0.84 CNR1 (0.48) CNR1CNR2MEN1CYP1A2CYP2D6
SCHEMBL17768668 0.84 CNR1 (0.49) CNR1CNR2MEN1CYP1A2CYP2D6
SCHEMBL17768761 0.84 KMT2A (0.44) MEN1CYP1A2CYP2D6HPGDCYP2C19
SCHEMBL17768692 0.84 CNR1 (0.46) CNR1CNR2MEN1CYP1A2CYP2D6
SCHEMBL17769058 0.82 ADORA2A (0.41) ADORA2AADORA1ADORA2B
SCHEMBL17768859 0.82 ADORA2A (0.47) MEN1CYP1A2CYP2C19KMT2AKLKB1
SCHEMBL17768901 0.82 CNR1 (0.46) CNR1CNR2HSD17B13P2RX7ADORA2A
SCHEMBL17769086 0.81 ADORA2A (0.51) ADORA2AADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2019-11-12 — — US claimed
US-20180327385-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2018-11-15 — — US claimed
EP-3220910-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES Merck Sharp & Dohme Corp. (US) 2017-09-27 — — EP claimed
WO-2016081290-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2016-05-26 — — WO claimed
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2019-11-12 — — US disclosed
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2019-11-12 — — US disclosed
US-20180327385-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2018-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties ADORA2A, ADORA1, ADORA3 CNR1 85/4885CNR2 222/4885MEN1 2777/4885
US-20180327385-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES ADORA2A, ADORA1, ADORA3 CNR1 85/4885CNR2 222/4885MEN1 2777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback